Adoptively transferred tumor-specific cells can mediate tumor regression in cancers refractory to conventional therapy. Autologous polyclonal tumor-specific cytotoxic T cells (CTLs) generated from peripheral blood and infused into patients with metastatic melanoma show enhanced persistence, compared with equivalent numbers of more extensively expanded monoclonal CTLs, and are associated with complete remissions (CRs) in select patients. We applied high-throughput T cell receptor V sequencing (HTTCS) to identify individual clonotypes within CTL products, track them in vivo after infusion, and then deduce the preadoptive transfer (endogenous) frequencies of cells ultimately responsible for tumor regression. The summed in vivo posttransfer frequencies of the top 25 HTTCS-defined clonotypes originally detected in the infused CTL population were comparable with enumeration by binding of antigen peptidehuman leukocyte antigen multimers, revealing that quantitative HTTCS is a reliable, multimer-independent alternative. The polyclonal CTL products were composed predominantly of clonotypes that were of very low frequency (VLF) in the endogenous samples, often below the limit of HTTCS detection (0.001%). In patients who achieved durable CRs, the composition of transferred CTLs was dominated (57 to 90%) by cells derived from a single VLF clonotype. Thus, HTTCS now reveals that tumor-specific CTLs enabling long-term tumor control originate from endogenous VLF populations that exhibit proliferative or survival advantages. Along with results indicating that naïve cell populations are most likely to contain cells that exist at VLF within the repertoire, our results provide a strong rationale for favoring T cells arising from VLF populations and with early differentiation phenotypes when selecting subset populations for adoptive transfer.
INTRODUCTION
Adoptive transfer of tumor-specific cytotoxic T cells (CTLs), a strategy demonstrating the capacity to eliminate cancer in an increasing number of settings, requires the in vivo establishment of a robust, persistent population of tumor-specific cells to prevent tumor recurrences (1, 2) . Our group has used the endogenous autologous T cell repertoire of patients as a readily accessible source of antigen-specific cells. In this approach, bulk peripheral blood mononuclear cells (PBMCs) are repetitively stimulated by dendritic cells pulsed with specific human leukocyte antigen (HLA)-restricted peptides from tumor antigens to increase the frequency of antigen-specific T cells. In our initial efforts, the responding cells were cloned by limiting dilution, one T cell clone was selected for expansion, and thus CTL infusion products represented progeny from one expanded cell (3) (4) (5) (6) (7) (8) . This strategy facilitated tracking by quantitative polymerase chain reaction (PCR)-based approaches, using primers flanking the clonal complementarity-determining region 3 (CDR3) (5, 7) . However, such monoclonal T cell products exhibited only a short survival in vivo (<14 days) in most of the patients, likely reflecting the extensive expansion required to attain therapeutic cell doses from a single reactive T cell in vitro and the associated terminal differentiation (3, (9) (10) (11) .
The availability of high-speed cell sorting based on peptide-major histocompatibility complex (pMHC) binding now enables infusion of CTLs that stem from a polyclonal tumor-specific repertoire (12) . Additionally, in both murine and human studies, CD8 + T cell culture conditions that include exposure to interleukin-21 (IL-21) during in vitro priming have been shown to facilitate greater expansion of the antigenresponding cells with less apoptosis (13) (14) (15) (16) (17) . By using such strategies, therapeutic cell doses can be produced by ex vivo expansion in 4 to 6 weeks rather than 3 to 4 months, and the tumor-specific cells generated have a higher replicative capacity and less terminally differentiated phenotype in vivo (8, 12, 18) . As a likely consequence of such technologies, infusion of polyclonal CTLs now produces enhanced in vivo persistence (>6 months) in a larger fraction of patients, which correlates with long-term tumor regression and improved disease control in a subset of patients (19, 20) .
Ample evidence suggests that the nature of the original parent T cell population is critical in determining the in vivo behavior of the expanded and infused CTLs (10, 17, (21) (22) (23) . To elucidate the factors that might contribute to the persistence of these polyclonal, IL-21-primed CTLs that leads to clinical responses, we investigated the endogenous frequencies of the infused clonotypes that contribute to mediating and sustaining tumor regression. In the case of autologous adoptive transfers, expanded or infused polyclonal tumor-specific T cells necessarily originate from a patient's preexisting circulating T cell repertoire. After ex vivo stimulation and culture, the phenotype and frequency of the expanded CTLs are generally sufficiently altered such that the qualities of the parent cells cannot be determined from the characteristics of the cells at the time of infusion (22) . However, the CTLs that persist express or acquire phenotypic and functional characteristics associated with long-lived memory T cells, including markers associated with survival (CD28, CD27, and CD127) (24, 25) and lymph node homing (CD62L and CCR7) (26, 27) , and exhibit the capacity 1 for polyfunctional cytokine production [interferon- (IFN-), tumor necrosis factor-, and IL-2] (28), suggesting that some of these characteristics are critical for persistence and tumor control (20) .
We therefore used high-throughput T cell receptor V sequencing (HTTCS) to sequence T cell receptor (TCR) V regions in a massively parallel fashion and thereby assess clonotype evolution after infusions, determine the contribution of distinct cells, and investigate the original source of the cells whose progeny most likely made a major contribution to mediating tumor regression or control.HTTCS can discern individual TCR clonotypes in a polyclonal population with a limit of detection of 1 of 100,000 (0.001%) (29) (30) (31) , and we first assessed whether this could enable in vivo tracking of the potentially thousands infused individual tumor-specific clonotypes. After demonstrating the accuracy of this approach, we then applied HTTCS to a set of 10 patients with metastatic melanoma who had detectable frequencies of transferred T cells after infusions. All patients had received polyclonal IL-21-primed T cell products expanded from unselected circulating T cell populations. We investigated the number of clonotypes that persisted after infusions, their individual frequencies, and the characteristics of the original source of the cells whose progeny most likely made a major contribution to mediating tumor regression or control.
RESULTS

Validation of HTTCS for tracking the frequency of transferred monoclonal CTLs in vivo
Among patients (Pt) who received monoclonal (M) T cells in a previous study (on "Protocol #2140" in Materials and Methods) (7), we analyzed the 2 (of 11 infused) in whom the transferred cells were detectable in vivo for >40 days after infusions (Table 1 ). Pt M2140-1 was infused with cells expanded from a melanoma-specific CD8 + T cell clone: 99.4% of the cell infusion product bound the HLA A*0201-restricted melanoma-associated antigen recognized by T cells 1 (MART1) epitope (AAGIGILTV) (A2/MART1) pMHC multimer (Fig. 1A) . HTTCS revealed that one clonotype comprised 99.7% of all TCR reads; 29 other clonotypes detected with frequencies ≥0.001% (table S1) comprised the remaining 0.3% and were likely bystander or contaminant clonotypes derived from the irradiated allogeneic PBMCs used to expand the cells (Fig. 1B, upper pie plot) . Pt M2140-2 was infused with CD8 + T cells recognizing the HLA B*4402-restricted Tyrosinase 192-200 epitope (B44/Tyr), for which a pMHC multimer could not be synthesized. The cell product included a total of 868 clonotypes, of which the most prevalent single clonotype represented 94% of all TCR reads (Fig. 1B, lower pie plot) . For both patients, the most prevalent HTTCS-detected clonotype was confirmed as the infused CTL clone by TCR V quantitative PCR (table S2) . We then compared the posttransfer in vivo frequencies of the most prevalent clonotype in each infusion product, as assessed by HTTCS, peptide-HLA multimer binding, and/or TCR V quantitative PCR. For Pt M2140-1, frequencies obtained by HTTCS were 42.1, 0.84, and 0.61% of total TCR reads in PBMCs collected on days 4, 56, and 508 after transfer. By comparison, the frequencies by multimer staining were 40.0, 0.21, and 0.74%, and those by TCR V-specific PCR were 48.5, 0.57, and 0.28% (Fig. 1C, upper graph) . For Pt M2140-2, HTTCS frequencies were 21.5, 6.75, and 1.25% at days 4, 48, and 117 compared with 15.8, 3.0, and 0.71% using TCR V-specific PCR (Fig. 1C, lower graph) . Thus, for frequencies ≥0.001% of total T cells, HTTCS frequencies yielded results concordant to TCR V-specific PCR and pMHC multimer binding, suggesting that HTTCS can be used to quantitatively track the frequency of infused monoclonal CD8 + T cells in vivo.
HTTCS accurately tracks the in vivo frequencies of adoptively transferred polyclonal CTLs
We next analyzed PBMCs from 10 patients who had each received one infusion of 10 10 /m 2 polyclonal (P) CTLs specific for A2/MART1 on a previous study (on "Protocol #2225" in Materials and Methods and Table 1 ) (20) . HTTCS detected between 56 and 2036 (mean, 555.4) clonotypes in the polyclonal infusion products from Pt P2225-1 to Pt P2225-10 ( Fig. 2A) . The most prevalent clonotype comprised between 4 and 77% of the total cells in each infusion (mean, 33.3%), and the 25 most prevalent clonotypes together comprised between 35.0 and 99.9% (mean, 78.4%) of the total cell products. This HTTCS analysis was performed on infusion products selected for binding pMHC multimers with >99% purity. The limit of pMHC detection is typically ≥0.01% of CD8 + T cells, which is at least 10-fold less sensitive than HTTCS. Thus, HTTCS of infusion products that have been selected by pMHC multimer binding is likely to also include contaminant clonotypes. To avoid tracking these bystander clonotypes after adoptive transfer, we excluded from analysis those clonotypes that had higher frequencies in preinfusion PBMCs compared with their frequencies within the CTL products, because these clonotypes likely reflected nonexpanded bystander cells that decreased in frequency through the cell culture process (table S3) . A total of 86 clonotypes (average, 0.014% of total CTL products) with frequencies of 0.001 to 8.85% (mean, 0.35%) were thus identified and removed from our analysis. Tracking the sum of the frequency of all expanded and infused clonotypes by HTTCS yielded nearconcurrent results with those obtained by tracking pMHC multimer binding for all patients who received polyclonal products (Fig. 2B) . Thus, HTTCS appears to accurately track the in vivo frequencies of infused polyclonal CTLs.
In vivo specific clonotype frequencies increase as a consequence of adoptive transfer To affirm that the postinfusion increase in clonotype frequencies is a reproducible consequence of the CTL infusions, we assessed the frequency of individual infused clonotypes for two patients who each received two polyclonal infusions, 30 or 37 days apart ("Protocol #2504" and "Protocol #2558" in Materials and Methods and Table 1 ) (32) . Although the clonotypes constituting the largest fraction of the patients' first and second infusates were shared, clonotype frequencies did vary as a likely consequence of the culture process, which uses an aliquot of the first CTL culture or infusion to expand sufficient cells for a second infusion (Fig. 3A) . The sum of all shared clonotypes was tracked in PBMCs before and after each infusion (Fig. 3B) , as was the individual contribution of the top 25 and all 10 clonotypes for Pt P2504-1 and Pt P2558-1, respectively (Fig. 3C) . Before infusions, all clonotypes were detected in PBMCs with frequencies of <0.01% (maximum, 0.0097; median, 0.001%) and 0.09% (maximum, 0.085%; median, 0.0028%) for Pt P2504-1 and Pt P2558-1, respectively. The frequency of the clonotypes peaked between days 1 and 7 after the first infusion (Pt P2504-1: maximum TCR sequence 2, 1.5%; median for first 25 clonotypes, 0.06%; Pt P2558-1: maximum TCR sequence 5, 2.73%; median for all 10 clonotypes, 0.35%), and the frequencies decreased over 14 or 30 days to near or at baseline levels. The same clonotypes then peaked again 1 to 7 days after the second infusion, albeit at lower frequencies (Pt P2504-1: maximum TCR sequence 11, 0.64%; median, 0.05%; Pt P2558-1: maximum TCR sequence 1, 0.68%; median, 0.15%). Thus, the postinfusion changes in clonotype frequency appear to be a consequence of the infusion of antigen-specific CTLs and not coincidental variations within the endogenous TCR repertoire. Notably, for these two patients, no correlation could be established between the frequency of the clonotypes in the infused product and the peak frequencies after infusion. (33), 2 had partial remissions (PRs), 3 had stable diseases (SDs), and 3 had progressive diseases (PDs) as best response (table S4) (19, 20) . The frequencies of the first 25 most prevalent clonotypes detected in each cell product were individually tracked in vivo after adoptive transfer (Fig. 4A , colored lines), as were the sum of the remaining clonotypes ( Fig. 4A , gray lines). In the two patients who achieved CRs after infusion (Pt P2225-1 and Pt P2225-7), only one individual clonotype remained detectable at sustained frequencies higher than those of other infused clonotypes (0.056% at day 280 and 0.093% at day 175 after infusion for Pt P2225-1 and Pt P2225-7, respectively) and represented most (>99%) of the detected antigen-specific cells after infusion ( (table S5) (7, 20) , these findings indicate that the immunodominant CTLs had the capacity to expand and persist. For the remaining patients, the average t 1/2 of clonotypes after transfer was 53 and 31 days for patients who achieved a PR as best response (Pt P2225-9 and Pt P2225-10); 44, 46, and 21 days for patients who achieved an SD (Pt P2225-2, Pt P2225-4, and Pt P2225-6); and 13, 15, and 14 days for patients who progressed (Pt P2225-3, Pt P2225-5, and Pt P2225-8). When all clonotype t 1/2 's were grouped according to patients' best response (Fig. 4C ), the t 1/2 differences were statistically significant between patients who obtained CRs, PRs, SDs, and PDs. Thus, prolonged in vivo persistence of transferred clonotypes is associated with, and presumably important for, tumor control by transferred CTLs.
Preexisting clonotype frequencies provide insights into the nature of persisting CTLs
The number of clonotypes comprising the polyclonal cell products for Pt P2225-1 to Pt P2225-10 was between 56 and 2036, with a median of 262.5 clonal sequences (table S2) . However, most clonotypes present in cell products (range, 43 to 1275; median, 160) were detected by HTTCS, with frequencies below 0.001% (the limit of detection), in PBMCs obtained before and after infusion and constituted only a minor fraction of the total infusion product (range, 0.82 to 24.7%; median, 2.26%) (Fig. 5A, gray areas) . As stated before, a clonotype with a frequency in the CTL product that was less than its corresponding frequency in the preinfusion PBMCs was defined as having not expanded during the culture process (table S2, bottom row). These clones comprised a minor fraction of the final infusion product, with a median of 0.02% (range, 0 to 0.61%) (Fig. 5A , purple areas), and were not further monitored. We found that clonotypes detected in any postinfusion PBMC sample, but not detected in preinfusion samples (range, 10 to 205; median, 56 sequences), were the dominant components of the final cell product (range, 74.68 to 98.97%; median, 97.67%) (Fig. 5A, blue areas) , implying preferential expansion from individual P2225-10 P2225-9 P2225-8 P 2 2 2 5 -1 P 2 2 2 5 -7 P 2 2 2 5 -9 P 2 2 2 5 -1 0 P 2 2 2 5 -2 P 2 2 2 5 -4 P 2 2 2 5 -6 P 2 2 2 5 -3 P 2 2 2 5 -5 P 2 2 2 5 -8 parental clonotypes with frequencies <0.001%, that is, a very low frequency (VLF) population. The immunodominant clonotypes in both patients who achieved CRs (Pt P2225-1 and Pt P2225-7) (Fig. 4, A and B, red arrows) were derived from their respective VLF populations. Clonotypes expanded in the cell infusion product that were detectable in PBMCs before infusion were less prevalent (range, 0 to 6; median, 2 sequences), comprising <10% (range, 0 to 9.22%; median, 0.03%) of the final cell products that were infused (Fig. 5A, orange  areas) . The frequencies of all expanded clonotypes were summed at multiple time points after infusion (Fig. 5B , solid red circles) and further subdivided into previously undetected clonotypes (Fig. 5B , open blue circles) versus previously detected clonotypes (Fig. 5B , orange open circles). Previously undetected clonotypes represented most of the cells in both infusion products and the detected clonotypes in posttransfer PBMCs, whereas previously detected clonotypes comprised a small fraction of infused products and a minority of posttransfer clonotypes.
To assess the likelihood that the preferentially expanded and infused clonotypes originated from a distinct parental T cell subpopulation, we assessed the propensity for clonotypes present in the three sets of normal donor PBMCs to exhibit a mostly antigen-experienced or naïve phenotype. Overall, clonotypes with frequencies <0.001% in PBMCs were 15 times more likely (72 ± 2% versus 5 ± 3%) to have originated from a CD3 
DISCUSSION
The use of HTTCS to examine TCR clonotypes of defined antigen specificity before infusion, through in vitro culture and after adoptive transfer, has provided a means to monitor the accumulation and in vivo persistence of individual clonotypes within a polyclonal population. This technology provides concordant results with frequency analyses by quantitative PCR of defined TCRs, which has more limited utility but can be used for tracking monoclonal cell products, and by pMHC multimer stains, which can be used to track polyclonal and monoclonal products but does not distinguish individual clonotypes (5, 7, 20, 34, 35) . HTTCS essentially provides a "natural barcode sequence" through the specific CDR3 TCR sequences of all clonotypes in an infused CTL cell product, enabling the identification of the cell or clonotype of origin within preinfusion donor PBMCs, measuring the expansion of each individual clonotype in the infusion product, and monitoring their individual in vivo fates after infusions (29) (30) (31) . These results can be correlated with clinical outcomes, which should facilitate the development of methods to preferentially isolate or generate cells that will have greater therapeutic efficacy.
We were surprised to observe that the vast majority of CTLs expanded in the infusion product originated from rare T cells. To increase the probability of generating autologous antigen-specific cells for adoptive transfer, the culture methods used in this study were aimed at expanding as many T cells as possible, without regard for a specific substrate T cell subset (20) . Thus, autologous MART1-specific T cells "competed" with each other in the culture system, and certain clonotypes with preinfusion frequencies <0.001% demonstrated an increased fitness and preferentially expanded. These were also the cells that comprised most of the antigen-specific cells that were detectable and persisted after infusion. Thus, the culture system fostered the expansion of fit cells that, despite having the capacity to recognize the tumor antigen, had a lower likelihood of already having been expanded in vivo in the tumor-bearing patient. By contrast, tumor-specific clonotypes that were more abundant in preinfusion PBMCs, with frequencies >0.001%, were generally less numerous in the final cell products and persisted less robustly in vivo after infusion, suggesting that these cells both expanded less well ex vivo and were less fit for survival after infusion. This latter observation is consistent with the poor expansion of tumor-specific cells that have been driven to exhaustion by a persistent antigenic burden (36) .
It is known that the qualities of the parent T cell from which tumorspecific CTLs originate before ex vivo expansion play a critical role in in vivo persistence, survival, and proliferation after transfer (1, 2) . CD8 + T cells can be separated into distinct subsets based on phenotypic markers that distinguish cells with different molecular programs and biologic functions. These CD8 subsets include T N and antigenexperienced cells, with the latter further subdivided into at least memory stem cells (T SCM ), central memory cells (T CM ), effector memory cells (T EM ), and terminal effector cells (T eff ) (10, 14, 17, 21, 22, 37, 38) . In prevention models, T CM are generally superior to T EM , presumably reflecting the distinct ability of T CM to form long-lasting memory, rapidly proliferate and expand after reencountering antigen, and produce abundant differentiated T EM (10, 21, 22) . By contrast, in therapy models of established tumors and of chronic infection, transferred cells derived from T N are generally superior to T CM , with an enhanced ability to provide sustained proliferation and in vivo expansion, leading to enhanced persistence and antitumor activity. This likely reflects both the greater replicative potential of T N -derived cells and the fact that T CM may already be programmed to undergo apoptosis or become functionally exhausted if stimulation persists and the antigen is not rapidly cleared (17, 23) . Within the T N compartment (CD45RA + 62L + ), the small subset of T SCM , distinguished by CD95 expression, appeared to retain the plasticity of T N and the self-renewal capacities of T CM (38) , functioned better than T CM in tumor therapy models, and persisted for years after transfer into humans (39-41).
Although available clinical reagents could not distinguish the origin of cells at the time of infusion because expanded CTLs derived from T N , T CM , or T EM mostly display a differentiated T EM phenotype after in vitro expansion (8, 20, 22) , our data set does provide insights into the likely origin(s) of the most effective cells. All cells obtained from the patients were stimulated with antigen-pulsed dendritic cells in the presence of IL-21 that facilitates the expansion of antigen-specific CTLs with low initial endogenous frequencies (15) . The effects of IL-21 exposure during priming of antigen-specific CD8 + T N have been best characterized and shown to help imprint a central memory program after antigen-specific stimulation, with limited differentiation of the expanded cells promoting survival, expansion, and in vivo persistence after infusion in murine models and human trials (8, 14, 42, 43) . However, the effect of IL-21 on previously exposed antigen-experienced memory cells during stimulation is less clear (43, 44) . Our analysis of normal donors suggests that clonotypes with PBMC frequencies <0.001% were 15 times more likely to be included in a CD45RA + subset, which includes mostly T N but also T SCM , compared with CD45RA − subsets that include T eff , T EM , and T CM . These findings are consistent with murine studies, where antigenspecific naïve precursor frequencies were estimated at ≤1 of 200,000 cells (45) and where most of the naïve CD8 T cell TCR sequences were found at a very low clonotype frequency (46) . Together, these data support the notion that antigen-naïve T cells are included in VLF populations. Although speculative, cells derived from VLF populations in our study might have been more likely to originate from a naïve rather than antigen-experienced subset. However, this could not be ascertained because of the logistical impossibility of sampling all preinfusion cells to obtain their phenotypes (7, 20) . It is plausible that some T CM and T SCM may also be found among the VLF populations, because these early differentiation phenotypes may have experienced limited in vivo expansion (38) . However, regardless of origin, parent cells whose progenies have the potential to ultimately persist, either assisted by IL-21 exposure or due to their intrinsic nature, are rare in the repertoire. By contrast, in vivo expanded cells with higher intrinsic frequencies are apparently not suitable substrates for achieving sustained responses by T cell infusion.
Our findings also show that within VLF populations, only a minority of CTLs are poised to produce offspring that can mediate sustained clinical responses. In this series of patients with metastatic melanoma, HTTCS tracking of infused clonotypes showed that the antigen-specific response in PBMCs of patients who reached CRs was largely dominated by a single immunodominant CTL clone, derived from a VLF population, which remained detectable at high frequencies over time. Although no pre-or posttumor biopsies were obtained from these patients to assess the presence of these clonotypes at the tumor site, the development of vitiligo in Pt P2225-1 (19) suggests an ongoing MART1-specific on-target, off-tumor effect. Along with the capacity of the immunodominant CTLs for sustained proliferation, reflected by their Ki67 expression and markedly prolonged t 1/2 (>100 days) in PBMCs compared with other simultaneously transferred clonotypes, these CTLs were likely instrumental for tumor elimination either through a direct anti-MART1 effect or by facilitating the development of secondary responses (19, 20) . For these two patients, only 1 of 56 (1.8%) and 1 of 76 (1.3%) infused clonotypes persisted and mediated or contributed to antitumor responses. These results are reminiscent of the proliferation and expansion of a very limited number of T cell clones at the tumor site in patients who presented clinical responses to immunomodulatory agents (47) .
The application of HTTCS to this clinical trial has provided unique insights by enabling tracking of individual clonotypes. Whether the properties of the parental cells from which the clonotypes were derived, and/or the affinity of the specific TCRs, conferred superior efficacy in the patients who experienced CRs remains unclear. Because long-term T cell survival can be enhanced by antigenic exposure, cells that carry high-affinity TCRs that can signal in the context of low levels of antigen presentation (2, 48, 49) , as is the case for most "self" tumor antigens (50) , are likely to have a postinfusion survival advantage compared with those that carry low-affinity TCRs (51) . Of the 10 patients we studied, only 2 of 4722 MART1-specific infused clonotypes (0.04%) demonstrated an immunodominant antitumor effect. Thus, a better understanding of such TCRs, and the intrinsic cellular properties associated with this rare feature, could direct strategies to endow cell therapy products with enhanced antitumor efficacy. Such TCRs can be identified by HTTCS and are paramount candidates for isolation use in adoptive T cell therapies, in which TCR genes are transduced into optimal T cell subsets for patients with appropriately matched HLA types. This strategy might be used to broadly confer antitumor efficacy to a wider range of patients with metastatic diseases. (7). Pt M1 and Pt M2 received CTLs specific for A2/MART1 and HLA B*4403-restricted Tyrosinase [192] [193] [194] [195] [196] [197] [198] [199] [200] (SEIWRDIDF), respectively. We specifically analyzed the 2 of 11 patients who received monoclonal products and demonstrated postinfusion in vivo persistence for a direct assessment of the equivalence of multimer staining, CDR3 PCR, and HTTCS on a unique CTL clone. Protocol #2225. Pt P2225-1 to Pt P2225-10 with metastatic melanoma received cyclophosphamide (300 mg/m 2 ) before the infusion of 10 10 polyclonal A*0201-restricted MART1 [27] [28] [29] [30] [31] [32] [33] [34] [35] CTLs/m 2 , immediately followed by low-dose subcutaneous IL-2 and ipilimumab (3 mg/kg; anti-CTLassociated protein 4, YERVOY; Bristol Myers Squibb) (52) every 3 weeks for a total of four doses (NCT 00871481) (20) . Radiologic responses were evaluated after infusion according to the IrRC ( fig. S1) (33) . Compared with monoclonal products, a higher fraction of polyclonal products expressed the markers CD27, CD28, and CD127 associated with memory. Whereas 100% (10 of 10) of polyclonal products persisted, only 18% (2 of 11) of monoclonal products persisted beyond 40 days in vivo ( 6 IU) to a pancreatic metastasis and followed by lowdose subcutaneous IL-2. Thirty-one days later, the patient received the same cell dose, this time preceded by a single 8-Gy fraction of radiation to a remaining metastasis, followed by 14 days of low-dose subcutaneous IL-2.
MATERIALS AND METHODS
Clinical protocols and patient characteristics
Generation and expansion of monoclonal tumor-specific CTL products (without IL-21) For protocol #2140, which involved monoclonal tumor-specific cells, cell processing was as previously described (7) . Briefly, PBMCs were collected by leukapheresis, and all ensuing ex vivo manipulations were performed in the clinical Good Manufacturing Practices Cell Processing Facility of the FHCRC (12) . Donor PBMCs were stimulated three times for 7-to 10-day cycles, with autologous DCs pulsed with the A2/MART1 peptide (AnaSpec) at a DC-to-effector ratio of 1:2 to 10 to obtain sufficient frequencies (>5%) of MART1-reactive CD8 + T cells. On day 2 of each stimulation, the  c -chain cytokines IL-2 (12.5 IU/ml), IL-7 (5 ng/ml), and IL-15 (1 ng/ml) were added. Cultures that contained ≥5% specific CD8 + T cells, assessed by multimer analysis, were cloned by limiting dilution and then stimulated twice using the rapid expansion protocol (4) . CTL products were frozen, thawed, and washed before infusion for a total production time of 12 to 13 weeks.
Generation and expansion of polyclonal tumor-specific CTL products (with IL-21)
For protocols #2225, #2504, and #2586, polyclonal tumor-specific cell products were generated as previously described (12, 20) . Briefly, PBMCs were depleted of CD25 + T cells (Miltenyi Biotec Inc.) to eliminate regulatory T cells and were stimulated for 7 days twice with autologous DCs pulsed with MART1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . DC stimulations were supplemented with the same  c -chain cytokines plus IL-21 (30 ng/ml) on day 1. Cultures that contained ≥5% specific CD8 + T cells were clinical grade-sorted (BD Influx Cell Sorter, BD Biosciences) and stimulated twice using the rapid expansion protocol. The total production time was 6 weeks.
CTL tracking by pMHC multimers
The sensitivity of multimer staining was fixed at 0.1% of total CD8 + T cells for monoclonal products (7) and at 0.05% for polyclonal products, as previously described (20 
CTL tracking by quantitative PCR
Primers flanking the CDR3 region of infused melanoma-specific CTL clones were designed, as previously described (5, 7) . Total CD4 + and CD8 + T cells were determined by flow cytometry, and the following formula was used to determine TCR copies per 100 T cells: 100/([% total CD8 + T cells in each sample] + [% total CD4 + T cells in each sample]*[TCR copies/{-actin copies/2}*100]).
DNA extraction and immunosequencing
DNA was extracted from CTL products and whole PBMCs using Qiagen Maxi DNA isolation kits (Qiagen Inc.). TCR CDR3 regions were amplified, and 750 ng of extracted DNA was sequenced by Adaptive Biotechnologies Corp. using the "deep" resolution ImmunoSEQ assay, as previously described (53) . Raw sequence data were filtered using the Adaptive Biotechnologies website on the basis of the TCR V(D)J gene definitions provided by the International ImMunoGeneTics (IMGT) collaboration (54) using the IMGT database (www.imgt.org). Productive nucleotide sequences were used for all tracking experiments. The data were further filtered to exclude sequences with no identifiable V and J, removing PCR errors such as primer dimer and mispriming, as well as sequences with a raw read count <2, removing nucleotide sequencing errors (29) .
CTL tracking by HTTCS
Only cells that bound pMHC multimers were selected by flow cytometry before DNA isolation for HTTCS. The limit of detection of HTTCS was set to 0.001% for all TCR reads below which frequency could not be reliably determined (31) . Only clonotypes present in the CTL products were tracked in PBMCs obtained after infusions. The frequency of each clonotype detected by HTTCS is based on all TCR V reads from CD4 + and CD8 + T cells.
Normal donor sorts
PBMCs were collected from three healthy adult donors and processed into three populations for TCR sequencing, that is, whole PBMCs, flow-sorted CD3 
Statistical analysis
Correlation between values was obtained by HTTCS, multimer, and TCR PCR: the Pearson's R was calculated on the log TCR frequency using frequencies obtained by HTTCS and either percent multimer + T cells or TCR copies per 100 cells and treating each biological sample (i.e., time point) as an independent observation. P values were generated by normal approximation. Half-lives of persistent TCR clonotypes were determined using the formula t 1/2 = t/(log 2 [N 0 /Nt]). Only clonotypes that had at least three consecutive values above the limit of detection (0.001%) and for which R 2 was >0.3 were used in the analysis. Comparison of clonotype t 1/2 was obtained in patients grouped according to their best clinical response: the Wilcoxon rank sum test was used to obtain P values.
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